HOPE + HOPE
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout HOPE + HOPE
HOPE + HOPE is a phase 1 stage product being developed by Eisai for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01240408. Target conditions include Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01240408 | Phase 1 | Completed |
Competing Products
20 competing products in Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mFOLFOX regimen + Mitazalimab | Alligator Bioscience AB | Phase 2/3 | 35 |
| Intratumoral Mitazalimab + Intratumoral Nivolumab | Alligator Bioscience AB | Phase 1 | 26 |
| mRNA-2416 | Moderna | Phase 2 | 0 |
| Doxorubicin Hydrochloride Liposome Injection | Dr. Reddy's Laboratories | Phase 1 | 26 |
| E7389 | Eisai | Phase 1 | 29 |
| Veliparib | AbbVie | Phase 2 | 27 |
| AK-105 | Akeso | Phase 1 | 29 |
| XL820 | Exelixis | Phase 1 | 26 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 30 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 29 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 31 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 30 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 35 |
| pemetrexed | Eli Lilly | Phase 2 | 27 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 29 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 18 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 35 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 35 |